Date:12/2/2009

s defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release and the section under "Financial Outlook" contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incid
'/>"/>

SOURCE Simcere Pharmaceutical Group Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
4. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
5. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
6. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
8. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
9. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers